CovaSyn

Insights

Latest analyses and perspectives on AI in chemistry, pharma, and biotech.

Binding Site Druggability Prediction, Honestly Read
Explainer8 min read

Binding Site Druggability Prediction, Honestly Read

Binding site druggability prediction explained: how geometric pocket detection works, what the score means, and a real CovaFold run on KRAS G12C that.

June 9, 2026

ICH Q1E Shelf Life Calculation from Accelerated Data
Guide8 min read

ICH Q1E Shelf Life Calculation from Accelerated Data

ICH Q1E shelf life calculation from accelerated stability data: the method, a worked example with real Arrhenius output, and when extrapolation is not OK.

June 8, 2026

OOT vs OOS in Stability Data: Catching Drift Early
Explainer7 min read

OOT vs OOS in Stability Data: Catching Drift Early

Out of trend stability data explained: how OOT differs from OOS, when regression, CUSUM and Shewhart methods fire, and a worked CovaStab example.

June 7, 2026

Tool Calling vs Fine-Tuning for Scientific AI
Explainer8 min read

Tool Calling vs Fine-Tuning for Scientific AI

Tool calling vs fine tuning in science: why a purpose-built model plus an LLM caller beats a fine-tuned LLM on determinism, applicability domain and audit.

June 7, 2026

Screening Designs Compared: Fractional, PB and DSD
Comparison8 min read

Screening Designs Compared: Fractional, PB and DSD

Screening design comparison for DoE: fractional factorial vs Plackett-Burman vs definitive screening, with real run counts, resolution and power from.

June 5, 2026

PBT Assessment for Pharmaceuticals: Very Toxic Is Not PBT
Explainer8 min read

PBT Assessment for Pharmaceuticals: Very Toxic Is Not PBT

PBT assessment for pharmaceuticals: how P, B and T differ from GHS aquatic hazard, with real CovaTox ecotox output for three drug molecules.

June 3, 2026

DoE Residual Diagnostics: Shapiro-Wilk and Cook's D
Explainer7 min read

DoE Residual Diagnostics: Shapiro-Wilk and Cook's D

DoE residual diagnostics explained: what Shapiro-Wilk, Cook's distance and leverage actually tell you about an RSM fit, with real CovaDOE tool output.

June 2, 2026

Retention Time Prediction in HPLC Method Development
Explainer8 min read

Retention Time Prediction in HPLC Method Development

What retention time prediction in HPLC is actually good for, what it is not, and a worked impurity panel with real chromaopt_predict_rt outputs.

June 1, 2026

Immunogenicity Prediction for Antibodies: MHC-II Screening
Use Case8 min read

Immunogenicity Prediction for Antibodies: MHC-II Screening

Immunogenicity prediction for antibodies: how MHC-II epitope screening works, real CovaBio output on trastuzumab VH/VL, and what in-silico ADA risk cannot.

May 28, 2026

Central Composite vs Box-Behnken: Which Design, When
Comparison8 min read

Central Composite vs Box-Behnken: Which Design, When

Central composite vs Box-Behnken on the same 3 factors: real CovaDOE run counts, axial points, power and the corners each design does not visit.

May 27, 2026

Cpk vs Ppk: In Control Is Not the Same as Capable
Explainer8 min read

Cpk vs Ppk: In Control Is Not the Same as Capable

Process capability for pharma: what Cpk and Ppk actually measure, why a stable process can still miss target, and a worked CovaOPT example with real SPC.

May 26, 2026

ICH M7 automated: mutagenicity triage in seconds: a Losartan worked example
Use Case8 min read

ICH M7 automated: mutagenicity triage in seconds: a Losartan worked example

ICH M7 requires two (Q)SAR methods per impurity. On a Losartan worked example: 10 impurities classified in seconds, 5 probable mutagens identified: including the well-known azido impurity (AZBT). How CovaTox covers both methods in one call, and where the limits are.

May 24, 2026

CovaSyn MCP

Run scientific tools right inside your AI agent.

18 deterministic tool families, one MCP server.

Try CovaSyn MCP
Insights - 4 | CovaSyn